Lyell Immunopharma Newsroom

Express News | Lyell Immunopharma Files Prospectus Related to Resale From Time to Time by Selling Stockholders of up to 37.5 Mln Shares of Common Stock - SEC Filing

ReutersNov 29 16:21 ET

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts

BenzingaNov 12 07:00 ET

Express News | HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target

BenzingaNov 12 06:45 ET

Lyell Immunopharma Analyst Ratings

BenzingaNov 12 06:40 ET · Ratings

Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges

TipRanksNov 12 06:16 ET · Ratings

Positive Week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) Institutional Investors Who Lost 26% Over the Past Year

Simply Wall StNov 10 08:09 ET

Lyell Immunopharma Reports Q3 Net Loss $44.6M Vs. $50.9M Last Year

TipRanksNov 7 17:16 ET

Express News | Lyell Immunopharma : Our Strong Cash Position Enables US to Advance Our Pipeline Through Important Clinical Milestones and Fund Operations Into 2027

ReutersNov 7 16:44 ET

Lyell Immunopharma | 10-Q: Q3 2024 Earnings Report

SECNov 7 16:26 ET · Announcements

Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $34,000

MT NewswiresNov 7 16:19 ET

Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

SECNov 7 16:14 ET

Express News | Lyell Immunopharma Q3 Revenue USD 34 Thousand

ReutersNov 7 16:05 ET

Express News | Lyell Immunopharma Q3 Operating Income USD -50.505 Million

ReutersNov 7 16:05 ET

Express News | Lyell Immunopharma Q3 Operating Expenses USD 50.539 Million

ReutersNov 7 16:05 ET

Express News | Lyell Immunopharma Q3 Net Income USD -44.583 Million

ReutersNov 7 16:05 ET

Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Dow JonesNov 7 16:05 ET

Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.

BenzingaNov 6 12:07 ET

Lyell Announces Presentation of Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

GlobeNewswireNov 5 09:30 ET

Express News | Lyell Announces Presentation of Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 American Society of Hematology (Ash) Annual Meeting

ReutersNov 5 09:30 ET

Lyell Immunopharma Expects Its Cash Balance Will Fund Ops Into 2027 >LYEL

Dow JonesOct 31 16:02 ET